The value of AREG and MSLN levels in the adjuvant diagnosis of breast cancer
Authors:
Open Access
- 1 January 2025
- journal article
- Published by Francis Academic Press Ltd. in Academic Journal of Medicine & Health Sciences
- Vol. 6 (1)
Abstract
To explore the application value of the levels of amphotericin (AREG) and mesothelin (MSLN) in the auxiliary diagnosis of breast cancer. Serum samples were collected from 46 patients with pathological diagnosis of suspected breast cancer and 46 healthy controls, and the levels of AREG and MSLN were measured by enzyme-linked immunosorbent assay (ELISA) and other methods to analyse their relationship with clinicopathological features of breast cancer, and the diagnostic efficacy of the two individually and in combination was evaluated by statistical methods. Serum AREG and MSLN levels were significantly higher in breast cancer patients than in healthy controls, and they were correlated with clinicopathological features such as pathological type, lymph node metastasis and pathological stage. The diagnostic accuracy of the combined test was higher than that of the individual test. AREG and MSLN levels are valuable in the adjuvant diagnosis of breast cancer, and the combination of these two tests is expected to improve the early diagnosis of breast cancer and provide a more reliable basis for clinical treatment decisions.Keywords
This publication has 4 references indexed in Scilit:
- The value of AREG and MSLN levels in the adjuvant diagnosis of breast cancerAcademic Journal of Medicine & Health Sciences, 2025
- Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approachesDiscover Oncology, 2024
- Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal AdenocarcinomaCancers, 2023
- Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targetsSeminars in Cancer Biology, 2020